Melanoma musings: Dr Ascierto’s trial updates from ESMO

Melanoma musings: Dr Ascierto’s trial updates from ESMO

Publication date: Nov 05, 2019

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, examines and explains the key melanoma updates from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Dr Ascierto touches on various combination therapies, including ipilimumab and nivolumab in the treatment of stage IV, high-risk melanoma patients and the triplet combination of dabrafenib, trametinib, and pembrolizumab.

Concepts Keywords
Australia Clinical medicine
Barcelona Key melanoma
Bill Disease
Brain Melanoma
Broom Pain
Dove Paint room
Free Tree Tumor
Graph Breakthrough therapy
Ipilimumab Bristol-Myers Squibb
Iraq Antineoplastic drugs
Italy Cancer treatments
Manama Melanoma
Manorama Ipilimumab
Master Key Nivolumab
Mecca Dabrafenib
Melanoma Brain metastasis
Milan Trametinib
Mistrial
Monotherapy
Nibbler
Organ
Pain
Pillow
Placebo
Probation
Progressive
Refractory
Relapse
Spain
Spire
Toxicity
Tree
Triplet
Tyvek

Semantics

Type Source Name
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
disease MESH Tumor
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
drug DRUGBANK Dabrafenib
drug DRUGBANK Trametinib
drug DRUGBANK Pembrolizumab

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *